80 related articles for article (PubMed ID: 3480697)
1. The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award.
Hershman MJ; Habib NA; Ferro MA; Williamson RC; Wood CB
Am Surg; 1987 Dec; 53(12):691-4. PubMed ID: 3480697
[TBL] [Abstract][Full Text] [Related]
2. [A clinical study on the tumor associated antigen CA50 in the monitoring of genitourinary malignancies].
Li CL; Xu BZ; Chen ZZ
Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):148-51. PubMed ID: 7924868
[TBL] [Abstract][Full Text] [Related]
3. Urinary tissue factor levels in patients with bladder and prostate cancer.
Lwaleed BA; Francis JL; Chisholm M
Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
[TBL] [Abstract][Full Text] [Related]
4. [Value of carcinoembryonic antigen (CEA) in the diagnosis of malignant tumors of the urogenital tract].
Rost A; Kneppenberg U; Rost P
Helv Chir Acta; 1976 Jul; 43(3):271-8. PubMed ID: 947865
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
7. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary application of carbohydrate antigen CA-50 radioimmunoinhibition test in diagnosing and monitoring cancers].
Chen ZZ; Fan ZF; Su P
Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):436-8. PubMed ID: 2838242
[TBL] [Abstract][Full Text] [Related]
9. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
Hershman MJ; Habib NA; Kelly SB; Beynon J; Williamson RC; Davies PW; Wood CB
Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445
[TBL] [Abstract][Full Text] [Related]
10. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
Wechsler M; Lo Gerfo P; Feminella J; Lattimer JK
Trans Am Assoc Genitourin Surg; 1972; 64():85-7. PubMed ID: 4347503
[No Abstract] [Full Text] [Related]
11. Clinical experience with the carbohydrate antigen CA-50 in the serum of patients with prostatic carcinoma: a preliminary report.
Melloni D; Cacciatore M; Carreca I; Cigno A; Laconi A; Pavone-Macaluso M
J Exp Pathol; 1987; 3(4):369-73. PubMed ID: 2457664
[No Abstract] [Full Text] [Related]
12. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
13. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
15. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate.
Abel PD; Cornell C; Buamah PK; Williams G
Br J Urol; 1987 May; 59(5):427-9. PubMed ID: 3474046
[TBL] [Abstract][Full Text] [Related]
16. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
17. On reference values for tumor markers in prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Kallner A
Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
19. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
Hamami G
Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
[TBL] [Abstract][Full Text] [Related]
20. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
Gregersen B; Mommsen S; Svanholm H
Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]